Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Serena MatisMolecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-3023-0213
Giulia Elda ValentiDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0001-7077-7534
Nicola TraversoDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.
Cinzia DomenicottiDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-5003-7333
Barbara MarengoDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0003-3056-6569
Bruno TassoDepartment of Pharmacy, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-5636-5645
Adalberto IbaticiHematology and Cellular Therapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Emanuele AngelucciHematology and Cellular Therapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-6512-6080
Tiziana VaisittiDepartment of Medical Sciences, University of Torino, 10124 Turin, Italy.ORCID 0000-0002-3375-6985
Paola MontiNeuro-Oncology and Mutagenesis Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-1978-4998
Paola MenichiniNeuro-Oncology and Mutagenesis Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-0057-6184
Funding
European Union Horizon 2020 research and innovation program, Marie Sklodowska-Curie N. 101023721 to A.N. MazzarelloItalian Ministry of health Current Research 2022-24 to P. MenichiniItalian Ministry of Health 5x1000 fund 2021 to N. BertolaItalian Ministry of Health 5x1000 funds 2014-2016 to G.C.Italian Ministry of Health 5x1000 funds 2020 to P.Menichini and G. CutronaItalian Ministry of Health Alleanza Contro il Cancro (ACC) Hematology networkItalian Ministry of Health Current Research 2022-24 to S. MatisItalian Ministry of Health RF-2021-12374376 to G. CutronaUmberto Veronesi Foundation n. 5365 to A.N. Mazzarello
6 · The paper itself
Abstract
In Chronic Lymphocytic Leukemia (CLL), mutations at the
Indexed as
Amino Acid Transport System y+Bridged Bicyclo Compounds, HeterocyclicGlutathioneLeukemia, Lymphocytic, Chronic, B-CellPyrrolidinesQuinuclidinesSulfasalazineTumor Suppressor Protein p53ApoptosisCell Line, TumorCell SurvivalHumansMutationReactive Oxygen SpeciesAmino Acid Transport System y+Bridged Bicyclo Compounds, HeterocycliceprenetapoptGlutathionePyrrolidinesQuinuclidinesReactive Oxygen SpeciesSLC7A11 protein, humanSulfasalazineTP53 protein, humanTumor Suppressor Protein p53antioxidant defensesGSHoxidative stressP53PRIMA-1MetSLC7A11/xCT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting the p53/xCT/GSH Axis with PRIMA-1 · full record | OpenQuestion